Pediatric TCM Market Highlights: 11 Exclusive Products Shine Amid Strong Sales Growth
Jumpcan
Developer and Manufacturer of Chinese and Western Medicine and Health Products
Kanion Pharmaceutical
A large traditional Chinese medicine enterprise integrating R&D, production, and trade
Lunan Pharmaceutical
Comprehensive Pharmaceutical Group
Wonderful Content
Recently, the pediatric traditional Chinese medicine (TCM) market has seen renewed activity. Guizhou Sanli Pharmaceutical Joint Stock (Limited) Company's application for the protection of the TCM variety Kaihoujian Spray (Children's Type) has been accepted. So far this year, four applications for the protection of pediatric TCM varieties have been accepted. From 2019 to the present, five new pediatric TCM drugs have been approved for marketing, two products are under review for production, and 16 new drugs have been approved for clinical trials. Data from Menet shows that in the first three quarters of 2023, sales of pediatric TCM in key provinces’ physical pharmacies exceeded 4.5 billion yuan, with a year-on-year increase of nearly 10%.
FromTOP20 Overview,11 exclusive varieties shine brightly, with Longmu Zhuanggu Granules maintaining its position as the "best-seller"; 11 brands achieve double-digit growth rates, two of which grow by over 90%, and Yabao Pharmaceutical Group Co., Ltd.'s Dinggui Erbiti advances into the top three with a growth rate exceeding 30%; in terms of quantity, Sunflower Pharmaceutical Group Co., Ltd. has the most, with five brands on the list.
Up nearly 10%, Sunflower, Jianmin, and Jumpcan take the lead
Sales of Pediatric Traditional Chinese Medicine in Physical Pharmacies in Key Provinces of China (Q1-Q3, 2023) (Unit: Billion Yuan)
MiNei Network DataData shows that the sales scale of pediatric Chinese patent medicines in key provinces' physical pharmacies exceeded 4.5 billion yuan in the first three quarters of 2023, with a year-on-year increase of nearly 10%. From the perspective of the TOP20 group pattern, Sunflower Pharmaceutical Group Co., Ltd., Jianmin Pharmaceutical Group Co., Ltd., and Jumpcan ranked in the top three. Guizhou Sanli Pharmaceutical Joint Stock (Limited) Company was the fastest-growing enterprise in the top ten, rising to the seventh place with a growth rate of nearly 50%.
Pediatric TCM Subclass Pattern in Physical Pharmacies of Key Provinces in China, Q1-Q3 2023
In terms of subcategories, pediatric cough and expectorant medications, pediatric cold medications, pediatric anorexia medications, and pediatric nutritional supplements are the four main categories; pediatric antidiarrheal drugs have the fastest growth rate, exceeding 35%, followed by pediatric cold medications with over 25%. In terms of prescription types, the OTC market is the largest in scale, while RX has the fastest growth rate. Regarding dosage forms, powders/granules and solutions together account for a combined market share of over 80%.
TOP20 Released! 11 Exclusive Products Stand Out, Two Brands Increase by Over 90%
Top 20 Pediatric Traditional Chinese Medicine Products in Key Provinces' Physical Pharmacies in China (Q1-Q3 2023) (Unit: Billion Yuan)
Note: Less than 100 million yuan is indicated by *
Among the top 20 products, 13 have sales exceeding 100 million yuan, including Longmu Zhuanggu Granules,Pien Tze Huang Qing Re Granules for Children and Pien Tze Huang Fei Re Ke Chuan Granules for Children ranked in the top three.Longmu Zhuanggu GranulesIt is the only pediatric nutritional supplement listed. In terms of subcategories, there are 7 types of pediatric cough and phlegm medications, 6 types of pediatric anorexia medications, 4 types of pediatric cold medications, and 1 each of pediatric nutritional supplements, pediatric antidiarrheal medications, and other pediatric medications.
11 exclusive products, respectively Longmu Zhuanggu Granules (Jianmin Pharmaceutical Group Co., Ltd.), Xiao'er Chigui Qingre Granules (Jumpcan), Dinggui'er Umbilical Patch and Yiyajian Pi Ningjiao (Yabao Pharmaceutical Group Co.Ltd.), Xiao'er Feire Keke Oral Liquid and Qihu Zha Granules (Sunflower Pharmaceutical Group Co.,ltd.), Kaihoujian Spray (Children's Type) (Guizhou Sanli Pharmaceutical Joint Stock(limited)Company), Jinzhen Oral Liquid (Kanion Pharmaceutical), Xiao'er Xiaoji Zhike Oral Liquid (Lunan Pharmaceutical), Simotang Oral Liquid (Hunan Hansen Pharmaceutical Co., Ltd.), Xingpi Yang'er Granules (Guizhou Jianxing Pharmaceutical Co., Ltd.).
Top 20 Brands of Pediatric Traditional Chinese Medicine in Physical Pharmacies of Key Provinces in China (Q1-Q3, 2023) (Unit: Billion Yuan)
Note: Less than 100 million yuan is indicated by *
Among the top 20 brands, 10 have sales exceeding 100 million yuan. Yabao Pharmaceutical Group Co., Ltd.'s Dinggui'er Umbilical Patch has entered the top three with a growth rate of over 30%. Guizhou Jianxing Pharmaceutical's Xingpi Yang'er Granules and Yabao Pharmaceutical (Guiyang)’s Yiya Jianpi Gel are newly ranked brands. In terms of quantity, Sunflower Pharmaceutical Group Co., Ltd. has the most entries, with five brands on the list.
In terms of growth rate, 11 brands achieved double-digit growth. Among them, the growth rates of华润三九(雅安)药业's (Huarun Sanjiu (Yaan) Pharmaceutical)小儿止咳糖浆 (Pediatric Cough Syrup) and 敖东延边药业's (Aodong Yanbian Pharmaceutical) 小儿柴桂退热口服液 (Pediatric Chaigui Antipyretic Oral Liquid) both exceeded 90%; Guizhou Sanli Pharmaceutical Joint Stock(limited)Company's 开喉剑喷雾剂(儿童型) (Kaihoujian Spray (Children's Type)), Jumpcan's 小儿豉翘清热颗粒 (Pediatric Chiqiao Heat-Clearing Granules), and Sunflower Pharmaceutical Group Co.,ltd.'s (冀州) 小儿清肺化痰口服液 (Pediatric Lung-Clearing and Phlegm-Resolving Oral Liquid) all surpassed 40%.
Longmu Zhuanggu GranulesIt is an exclusive product of Jianmin Pharmaceutical Group Co., Ltd., which strengthens muscles and bones, harmonizes the stomach, and invigorates the spleen. It is used to treat symptoms such as excessive sweating in children, night terrors, poor appetite, indigestion, and delayed development. In the first three quarters of 2023, the sales volume of this product in key provinces' physical pharmacies exceeded 500 million yuan, with a year-on-year increase of 10.03%. Recently, Jianmin Group disclosed its 2023 annual report, showing record-high performance, with revenue surpassing 4 billion yuan and net profit exceeding 500 million yuan. This was mainly due to the revenue growth of leading products like Longmu Zhuanggu Granules and Qirui Weishu Capsules, as well as increased investment returns. Longmu Zhuanggu Granules is the top single product in the company's OTC product line. In the 2023 edition of the National Medical Insurance Drug List, the reimbursement restrictions were lifted, positively promoting the drug’s sales and promotion in hospitals. This has bolstered the company’s confidence to continue increasing R&D investment and accelerating the R&D process.
Ding Gui Er Umbilical PatchIt is an exclusive product of Yabao Pharmaceutical Group Co., Ltd., with the efficacy of strengthening the spleen, warming the middle, dispelling cold, and stopping diarrhea. It is mainly used as an adjuvant treatment for infantile diarrhea and abdominal pain. In the first three quarters of 2023, the product ranked among the top three in key provinces' physical pharmacies with a growth rate of 33.83%, achieving sales of over 200 million yuan. It is reported that Yabao Pharmaceutical Group adheres to the strategic development goal of "Pediatrics First," focusing on the development of three major pediatric products: Dinggui'er Umbilical Patch, Yiya Spleen-Strengthening Gel, and Children's Throat-Clearing and Heat-Relieving Oral Liquid. Among them, Dinggui'er Umbilical Patch has been on the market for over 30 years, consistently maintaining its leading position as the number one product in the category of external-use treatments for children’s diarrhea.
Four Pediatric Traditional Chinese Medicine Applications for Protection, Jianmin, Kanion, Yingtai Rui… New Class 1 Drugs on the Way
Pediatric Traditional Chinese Medicine Protection Applications Accepted Since the Beginning of This Year
Recently, the official website of the National Medical Products Administration showed that the application for the protection of the traditional Chinese medicine variety of Guizhou Sanli Pharmaceutical's Kaihoujian Spray (Children's Type) has been accepted. Prior to this, the applications for the protection of three pediatric traditional Chinese medicine varieties, including Lunan Houpu Pharmaceutical's Xiao'er Xiaoji Zhike Granules and Yabao Pharmaceutical Sichuan Pharmaceutical's Children's Qingyan Jiere Oral Liquid, were also accepted, with the application matter being initial protection. All four products are exclusive varieties.
Status of Pediatric Traditional Chinese Medicine Production Reports Under Review Since the Beginning of This Year
Source: MiNeiNet China Application Progress (MED) Database
In recent years, driven and supported by national policies, the research and development of pediatric traditional Chinese medicine (TCM) has significantly accelerated. So far this year, two Class 1 new drugs have been submitted for production: Xiaor Huangjin Zhike Granules by Beijing Dongfang Yunjia Pharmaceutical and Niuhuang Xiaor Tuire Patch by Jianmin Pharmaceutical Group Co., Ltd., both of which are currently under review.
From 2019 to present, five new pediatric traditional Chinese medicine (TCM) drugs have been approved for marketing in China, with two products under review for production; 16 new drugs have been approved for clinical trials. Among them, nine are classified as Category 1 new drugs, including Jiangsu Kanion Pharmaceutical Co., Ltd.'s Pediatric Jianpi Granules (Baby Joy) and Pediatric Foshao Harmonizing Granules, Yili Pharmaceutical (Luoding)'s Pediatric Yinlian Granules, and Yingke Rui (Tianjin) Innovative Medicine's Pediatric Erbai Pain-Relieving Granules. These drugs cover treatment subcategories such as pediatric anorexia medications and pediatric cold medications.
Source: MiNeiNet database, company announcements, etc.
— END —
